301015.SHE Qingdao Baheal Medical INC.

The Graham number of Qingdao Baheal Medical INC. cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

No fundamental analysis for Qingdao Baheal Medical INC. yet.

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and internationally. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; and liver disease drugs under the Fuzhenghuayu brand name. It also provides tumor and other severe drugs under the Utidelon, Gore Ning, Mai Ruibei, and Hai Ruisi brand names; diabe…

2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.

Qingdao Baheal Medical INC. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)

Dividend yield

3.41%

Forward dividend

0.57 CNY

Payout ratio

98.5%

Ex-dividend date

Jun 1, 2026

From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.

Company name

Qingdao Baheal Medical INC.

Ticker

301015.SHE

ISIN

CNE100004LR8

Exchange

Shenzhen Stock Exchange

Sector

Healthcare

Industry

Pharmaceuticals

Employees

2,493

Fiscal year end

December

Address

Building 1, No. 88 Tongbai Road, Qingdao, China, 266042

Phone

86 532 6777 3303

Website

baheal.cn

About Qingdao Baheal Medical INC.

Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and internationally. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; and liver disease drugs under the Fuzhenghuayu brand name. It also provides tumor and other severe drugs under the Utidelon, Gore Ning, Mai Ruibei, and Hai Ruisi brand names; diabetes drugs under the Naida, Feburic, and Naite brand names; and medical nutrition under the Nutrasumma brand name, as well as skincare under the Cactus brand name. In addition, the company offers ZAP-X, an AI radiosurgery robot for intracranial tumors and lesions; Cifu VAD, the fully magnetically levitated ventricular assist device; and AtriCure Bipolar Radiofrequency Ablation Isolator for the treatment of chronic atrial fibrillation. The company was incorporated in 2005 and is based in Qingdao, China. Qingdao Baheal Medical INC. is a subsidiary of Baiyang Pharmaceutical Group Co., Ltd.

• Mr. Gang FuChairman & GM · born 1970
• Mr. Zhen LiFinancial Director, Secretary, Director & Deputy GM · born 1982
• Mr. Xiaowei ZhuDeputy GM & Director · born 1963
• Ms. Yuan ZhangDeputy General Manager · born 1975
• Mr. Ting Wei WangDeputy General Manager · born 1978
• Ms. Bi Quan WangDeputy General Manager · born 1962
• Feng LiuHead of the Accounting Department & Accounting Supervisor